Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on Repligen (NASDAQ:RGEN) and increased the price target from $210 to $220.

February 15, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keybanc analyst Paul Knight has reaffirmed an Overweight rating on Repligen and raised the price target from $210 to $220.
The increase in price target by a reputable analyst like Paul Knight suggests a positive outlook on Repligen's stock, likely due to expected performance improvements or market conditions favoring the company. This endorsement can boost investor confidence, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100